Several other research firms have also commented on AIMT. ValuEngine lowered shares of Aimmune Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, November 29th. Wedbush reissued a buy rating on shares of Aimmune Therapeutics in a research note on Thursday, October 31st. Royal Bank of Canada cut their price objective on Aimmune Therapeutics to $50.00 and set an outperform rating for the company in a research report on Friday, August 9th. Goldman Sachs Group set a $27.00 target price on Aimmune Therapeutics and gave the company a hold rating in a research note on Friday, October 25th. Finally, Piper Jaffray Companies set a $60.00 target price on Aimmune Therapeutics and gave the company a buy rating in a report on Wednesday, October 9th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $43.11.
NASDAQ AIMT traded up $0.52 during trading hours on Friday, reaching $29.65. The company’s stock had a trading volume of 458,116 shares, compared to its average volume of 713,966. The stock has a market cap of $1.86 billion, a PE ratio of -8.08 and a beta of -0.03. Aimmune Therapeutics has a fifty-two week low of $16.95 and a fifty-two week high of $29.70. The company’s 50-day moving average is $27.62 and its two-hundred day moving average is $22.37. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.64 and a current ratio of 4.64.
In other news, CFO Eric Bjerkholt bought 1,550 shares of Aimmune Therapeutics stock in a transaction on Wednesday, September 18th. The shares were bought at an average cost of $22.57 per share, for a total transaction of $34,983.50. The transaction was disclosed in a filing with the SEC, which is available at this link. 13.75% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of AIMT. Price T Rowe Associates Inc. MD increased its stake in Aimmune Therapeutics by 11.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,246,604 shares of the biotechnology company’s stock valued at $109,234,000 after purchasing an additional 535,072 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Aimmune Therapeutics in the 2nd quarter worth about $10,835,000. Eventide Asset Management LLC boosted its stake in Aimmune Therapeutics by 11.1% in the 3rd quarter. Eventide Asset Management LLC now owns 3,084,000 shares of the biotechnology company’s stock worth $64,579,000 after buying an additional 309,000 shares during the last quarter. Millennium Management LLC purchased a new stake in Aimmune Therapeutics in the 3rd quarter valued at about $5,338,000. Finally, Nuveen Asset Management LLC purchased a new stake in Aimmune Therapeutics in the 2nd quarter valued at about $3,969,000. Institutional investors and hedge funds own 81.82% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Featured Article: How Do Mutual Funds Work?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.